

Press Release



Notice Regarding Change of Certified Public Accountants, etc.

TOKYO, May 25, 2026 - ASKA Pharmaceutical Holdings Co., Ltd. (TSE:4886, Head Office: Minato-ku, Tokyo) hereby announces that, at the Audit & Supervisory Board meeting held on May 25, 2026, it resolved to change in the certified public accountants, etc., who conduct audit certifications under Article 193-2, Paragraphs 1 and 2 of the Financial Instruments and Exchange Act. At the Board of Directors meeting held on the same day, it resolved to submit the proposal "Appointment of Accounting Auditors" to the 5th Ordinary General Meeting of Shareholders, scheduled to be held on June 24, 2026. Details are as follows.

1. Scheduled Date of Change

June 24, 2026 (scheduled date for the 5th Ordinary General Meeting of Shareholders)

2. Overview of the Certified Public Accountants, etc. Incoming and Outgoing Office

(1) Overview of the Certified Public Accountants, etc. Incoming Office

1) Name	Ernst & Young ShinNihon LLC
2) Location	1-1-2 Yuraku-cho, Chiyoda-ku, Tokyo Hibiya Mitsui Tower, Tokyo Midtown Hibiya
3) Executive Partners	Tetsuya Yoshida, Keisuke Kishi
4) Registration status under the Listed Company, etc. Auditor Registration System under the Certified Public Accountants Act	It has been registered.

(2) Overview of the Certified Public Accountants, etc. Outgoing Office

1) Name	Seiyo Audit Corporation
2) Location	1-22-10 Nishishinbashi, Minato-ku, Tokyo Nishishinbashi Annex Building, 2nd Floor
3) Executive Partners	Takuro Mitsunari, Takanori Ozeki, Kenichiro Makita

3. Reasons for Selecting the Audit Firm Listed in 2. (1) above as Candidate Certified Public Accountants, etc.

The reason the Audit & Supervisory Board selected Ernst & Young ShinNihon LLC as the candidate certified public accountants, etc. is that, in addition to the expectation of audits to provide a new perspective, the firm has established an audit system suited to the Company Group's global business expansion strategy and the standardization of audit systems. After comprehensively considering the firm's expertise in light of the Company's business operations, independence, quality control system, and global audit system, the Company determined that the firm is suitable

to serve as the Company's accounting auditor.

4. Date of Appointment of the Certified Public Accountants, etc. Outgoing Office

June 29, 2011

As the Company is a pure holding company established in April 2021 through a sole share transfer by ASKA Pharmaceutical Co., Ltd., the appointment date listed herein is that of ASKA Pharmaceutical Co., Ltd. prior to the establishment of the Company.

5. Opinions, etc. Presented in Audit Reports, etc. Prepared by the Certified Public Accountants, etc. Outgoing Office During the Most Recent Three Years

There are no applicable matters.

6. Reasons for the Decision on the Change or Circumstances Leading to the Change

Seiyo Audit Corporation, the Company's current certified public accountants, etc., will complete its term of office upon the conclusion of the 5th Ordinary General Meeting of Shareholders scheduled to be held on June 24, 2026. While the Company recognizes that the accounting audit conducted by the aforementioned auditing firm has been appropriate and reasonable, given the number of years the audit has been conducted and the Company Group's global business expansion strategy, the Company determined that an audit conducted from a new perspective could be expected. Accordingly, for the reasons described in Section 3 above, the Company has decided to newly appoint Ernst & Young ShinNihon LLC as the candidate certified public accountants, etc.

7. Opinions on the Reasons and Circumstances Described in Section 6 Above

(1) Opinions by the Certified Public Accountants, etc. Leaving Office

The Company has received a response stating that there are no particular opinions.

(2) Opinion of the Audit & Supervisory Board

The Board has determined that it is reasonable.

Media Contacts

ASKA Pharmaceutical Holdings Co., Ltd.

Corporate Planning Department

Tel: +81-3-5484-8366

Email: kouhou@aska-pharma.co.jp